AR125250A1 - Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas - Google Patents

Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas

Info

Publication number
AR125250A1
AR125250A1 ARP220100771A ARP220100771A AR125250A1 AR 125250 A1 AR125250 A1 AR 125250A1 AR P220100771 A ARP220100771 A AR P220100771A AR P220100771 A ARP220100771 A AR P220100771A AR 125250 A1 AR125250 A1 AR 125250A1
Authority
AR
Argentina
Prior art keywords
psilocybin
procedures
compositions
composition
manufacture
Prior art date
Application number
ARP220100771A
Other languages
English (en)
Inventor
David Philip Elder
Nigel Richardson
Original Assignee
Compass Pathfinder Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compass Pathfinder Ltd filed Critical Compass Pathfinder Ltd
Publication of AR125250A1 publication Critical patent/AR125250A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente divulgación proporciona composiciones farmacéuticas estables y sólidas que comprenden una cantidad terapéuticamente eficaz de psilocibina y uno o más excipientes farmacéuticamente aceptables. También se desvelan procedimientos de fabricación de dichas composiciones y uso de las mismas en el tratamiento de trastornos depresivos. Reivindicación 1: Una composición farmacéutica sólida y estable que comprende: una cantidad terapéuticamente eficaz de psilocibina; y uno o más excipientes farmacéuticamente aceptables, en la que, después del almacenamiento de la composición a 40ºC y el 75% de humedad relativa durante un mes, la potencia de la psilocibina en la composición disminuye en menos del 5% y el balance másico de la psilocibina y las sustancias relacionadas es superior al 97%.
ARP220100771A 2021-03-30 2022-03-30 Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas AR125250A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163168055P 2021-03-30 2021-03-30

Publications (1)

Publication Number Publication Date
AR125250A1 true AR125250A1 (es) 2023-06-28

Family

ID=81448508

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP220100771A AR125250A1 (es) 2021-03-30 2022-03-30 Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas
ARP220101430A AR126005A1 (es) 2021-03-30 2022-05-31 Composiciones de psilocibina, métodos de fabricación y métodos de uso de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP220101430A AR126005A1 (es) 2021-03-30 2022-05-31 Composiciones de psilocibina, métodos de fabricación y métodos de uso de las mismas

Country Status (14)

Country Link
US (1) US20240197758A1 (es)
EP (1) EP4312995A1 (es)
JP (1) JP2024512983A (es)
KR (1) KR20230175186A (es)
CN (1) CN117460498A (es)
AR (2) AR125250A1 (es)
AU (1) AU2022246987A1 (es)
BR (1) BR112023018472A2 (es)
CA (1) CA3210649A1 (es)
CO (1) CO2023013050A2 (es)
IL (1) IL305435A (es)
MX (1) MX2023011326A (es)
TW (1) TW202304466A (es)
WO (1) WO2022207746A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin
AU2022409230A1 (en) 2021-12-13 2024-06-20 Compass Pathfinder Limited Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
US12060328B2 (en) 2022-03-04 2024-08-13 Reset Pharmaceuticals, Inc. Co-crystals or salts of psilocybin and methods of treatment therewith

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186293B2 (en) 2005-03-23 2007-03-06 Bpsi Holdings, Inc. Agglomerated starch compositions
GB2571696B (en) * 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP2022523700A (ja) * 2019-01-30 2022-04-26 ダイヤモンド セラピューティクス インク． 心理性、認知性、行動性、および／または気分性の障害を処置するための方法、ならびに５ｈｔ受容体アゴニストを含む組成物
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin
US11766445B2 (en) * 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound

Also Published As

Publication number Publication date
WO2022207746A1 (en) 2022-10-06
MX2023011326A (es) 2023-10-03
KR20230175186A (ko) 2023-12-29
CN117460498A (zh) 2024-01-26
AU2022246987A1 (en) 2023-09-07
TW202304466A (zh) 2023-02-01
CA3210649A1 (en) 2022-10-06
EP4312995A1 (en) 2024-02-07
BR112023018472A2 (pt) 2023-10-10
US20240197758A1 (en) 2024-06-20
AR126005A1 (es) 2023-08-30
CO2023013050A2 (es) 2023-10-19
JP2024512983A (ja) 2024-03-21
IL305435A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
AR125250A1 (es) Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas
MX2021016085A (es) Derivados de benzisoxazol sulfonamida.
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
BR112021022335A2 (pt) Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
AR052062A1 (es) Composicion y metodo para tratar el asma
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
HUP0302474A2 (hu) Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR040434A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
PH12021551232A1 (en) Haloallylamine compounds and application thereof
PE20180398A1 (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
WO2021070200A3 (en) Stable compositions of (7as,2's)-2-oxoclopidogrel and its pharmaceutical salts
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
BR112022001567A2 (pt) Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias.
AR052567A1 (es) Combinacion de bambuterol e inhibidor de integrina
CL2023002871A1 (es) Composiciones nasales que comprenden alcaftadina
BR112023015272A2 (pt) Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas
MX2020008360A (es) Forma cristalina de bictegravir sodico.
AR048929A1 (es) Formas de dosificacion y metodos de tratamiento utilizando inhibidores de vegfr.
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
EA202290122A1 (ru) Фармацевтические композиции в форме геля, содержащие ксилоглюкан и спирты, для регулируемого высвобождения активных ингредиентов
BR112022003359A2 (pt) Composição de amida peptídica e método de preparação da mesma